Ketoconazole and Lopinavir and ritonavir interaction

Ketoconazole and Lopinavir and ritonavir: both prescribing labels flag this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.

Major

Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.

What the FDA labels say

From the Ketoconazole label · effective 2026-07-07

Major

Therefore, administration of potent enzyme inducers of CYP3A4 with ketoconazole tablets is not recommended.

Drug interactionsby drug classView label on DailyMed
Moderate

Drugs that may increase ketoconazole plasma concentrations Potent inhibitors of CYP3A4 (e.g., antivirals such as ritonavir, ritonavir-boosted darunavir and ritonavir-boosted fosamprenavir) may increase the bioavailability of ketoconazole.

Drug interactionsnames Lopinavir and ritonavirView label on DailyMed
Moderate

Coadministration of ketoconazole tablets with potent enzyme inducers of CYP3A4 may decrease the bioavailability of ketoconazole to such an extent that efficacy may be reduced.

Drug interactionsby drug classView label on DailyMed

From the Lopinavir and ritonavir (Kaletra) label · effective 2026-07-23

Major

Antifungals: ketoconazole*, itraconazole, voriconazole isavuconazonium sulfate* ↑ ketoconazole ↑ itraconazole ↓ voriconazole ↑ isavuconazonium High doses of ketoconazole (>200 mg/day) or itraconazole (> 200 mg/day) are not recommended.

Drug interactionsnames KetoconazoleView label on DailyMed
Major

Avoid use in patients with congenital long QT syndrome, those with hypokalemia, and with other drugs that prolong the QT interval.

Warnings and precautionsby drug classView label on DailyMed
Moderate

Potential for KALETRA to Affect Other Drugs Lopinavir/ritonavir is an inhibitor of CYP3A and may increase plasma concentrations of agents that are primarily metabolized by CYP3A.

Drug interactionsby drug classView label on DailyMed
Moderate

Although not observed in the KALETRA/ketoconazole drug interaction study, co-administration of KALETRA and other drugs that inhibit CYP3A may increase lopinavir plasma concentrations.

Drug interactionsby drug classView label on DailyMed
Moderate

Alternative antifungal therapies should be considered in these patients.

Drug interactionsby drug classView label on DailyMed

Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.

Open in the checker

Not medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.